title: Comparison Of Early-Stage High-Grade Serous Primary Fallopian Tube Cancers and Epithelial Ovarian Cancers: A Multicenter Study.
abstract: BACKGROUND
  We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC).
  
  
  METHODS
  22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data.
  
  
  RESULTS
  The mean age of HG-sPFTC patients was 59.4 ± 6.2 years, and that of HG-sEOC patients 55.2 ± 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75).
  
  
  CONCLUSIONS
  The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar.
authors.affiliation: Department of Gynecologic Oncology, Tepecik Education and Research Hospital, Izmir, Turkey.
authors.forename: Kemal
authors.initials: K
authors.lastname: Gungorduk
authors.forename: Aykut
authors.initials: A
authors.lastname: Ozdemir
authors.forename: Ilker
authors.initials: I
authors.lastname: Selcuk
authors.forename: Elcin
authors.initials: E
authors.lastname: Telli
authors.forename: Öztürk
authors.initials: Ö
authors.lastname: Şahin
authors.forename: Tayfun
authors.initials: T
authors.lastname: Toptaş
authors.forename: Levent
authors.initials: L
authors.lastname: Akman
authors.forename: Ahmet B
authors.initials: AB
authors.lastname: Güzel
authors.forename: Salih
authors.initials: S
authors.lastname: Taşkın
authors.forename: Tufan
authors.initials: T
authors.lastname: Öge
authors.forename: Özgü
authors.initials: Ö
authors.lastname: Güngördük
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gokçü
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
authors.forename: Levent
authors.initials: L
authors.lastname: Yaşar
authors.forename: Mustafa C
authors.initials: MC
authors.lastname: Terek
authors.forename: Hakan
authors.initials: H
authors.lastname: Ozan
authors.forename: Aydın
authors.initials: A
authors.lastname: Ozsaran
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Sancı
authors.forename: Mehmet A
authors.initials: MA
authors.lastname: Vardar
authors.forename: Mehmet M
authors.initials: MM
authors.lastname: Meydanlı
authors.forename: Ömer T
authors.initials: ÖT
authors.lastname: Yalçın
authors.forename: Fırat
authors.initials: F
authors.lastname: Ortac
authors.forename: Sinan
authors.initials: S
authors.lastname: Özalp
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant / Q000401:mortality / Q000706:statistics & numerical data; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D055088:Early Detection of Cancer; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D015995:Prevalence; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome; D014421:Turkey